CELG News and Press, Celgene Corporation From 06/25/19

Mergers is the sign of a healthy stock market AbbVie (ABBV) is buying the long-suffering Allergan (AGN) for 63 billion bucks. Long-term readers might remember me making a strong case to go long on AGN because of the charts, and then Carl Icahn got involved, so we were able to escape with som...

The FDA has removed the partial clinical hold on AbbVie's (NYSE: ABBV ) Phase 3 clinical trial, CANOVA , evaluating the combination of Venclexta/Venclyxto (venetoclax) and dexamethasone versus Celgene's (NASDAQ: CELG ) Pomalyst (pomalidomide) + dexamethasone in patients with relapsed/refr...

Aimed at getting timely sign-off from the U.S. Federal Trade Commission (FTC) on its planned takeover of Celgene (NASDAQ: CELG ), Bristol-Myers Squibb (NYSE: BMY ) says it will divest  arthritis med Otezla (apremilast). It expects the merger to close by year-end or early 2020. More...

Thinly traded MorphoSys AG (NASDAQ: MOR ) is up  5%  premarket on light volume in reaction to data from a Phase 2 clinical trial, L-MIND , evaluating tafasitamab (MOR208), combined with Celgene's (NASDAQ: CELG ) Revlimid (lenalidomide), in patients with relapsed/refractory diffu...

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTCȁ...

Deals and Financings Beijing's BeiGene ([[BGNE]]; HK: 06160) will receive a $150 million termination payment from Celgene (CELG) because Celgene will end its $1.4 billion partnership for ex-China rights to BeiGene's PD-1 candidate. The original deal included a provision that BeiGene's ti...

bluebird bio ( BLUE ) was one of my best medium-term investments between February 2017 and March 2018. Since then, I have been patiently waiting to find a point to reenter the stock for a long-term investment as the company transitions into a commercial-stage company. The recent EU approval of...

At the start of the year, 2019, Bristol-Myers Squibb (BMY) announced it was planning to acquire Celgene (CELG). The announcement was unexpected, leading to a massive run-up in Celgene’s stock price. The details have yet to be ironed out. However, current estimates show that it will li...

Investing in solid companies with reasonable valuations can be a simple and effective investment strategy for superior returns. Even better, if the company is distributing lots of cash to investors via dividends and buybacks, this provides an additional reason to buy the stock. A Quantitativ...

With very beneficial results obtained for the treatment of psoriasis, Dermavant Sciences ( DRMT ) is a name to be followed closely after the IPO goes live. Besides, the Phase 3 clinical results are expected in the first half of 2020. So, market participants willing to profit on this name shoul...